Sanigen KRX:188260KOSDAQ
세니젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days7
DART filings, 7 days0
Articles tracked7since Sep 11
In Q2 2026, Sanigen reported revenue of ₩3.8bn, down 55.5% year on year, and an operating loss of ₩405m. Sanigen (세니젠) appeared in 7 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 30 with 6 articles. The most common catalyst was tech & capacity (1).
Filing signals 4 quarters of losses Screener
Sanigen quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩3.8bn | -55.5% | −₩405m margin −10.6% | −₩145m |
| Q1 2026 | ₩3.3bn | -56.9% | −₩872m margin −26.3% | −₩898m |
| Q4 2025 derived check units | −₩4.9bn | – | −₩1.8bn | −₩3.2bn |
| Q3 2025 | ₩4.1bn | -38.5% | −₩908m margin −22.4% | −₩937m |
| Q2 2025 | ₩8.6bn | +50.8% | −₩791m margin −9.2% | −₩812m |
| Q1 2025 | ₩7.7bn | +62.2% | −₩891m margin −11.6% | −₩904m |
| Q4 2024 derived check units | −₩1.6bn | – | −₩1.8bn | −₩2.5bn |
| Q3 2024 | ₩6.6bn | +28.0% | −₩1.1bn margin −16.7% | −₩1.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Sanigen top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest Sanigen news Korean headlines
-
세니젠, 식중독 원인균 3종 동시 진단키트 개발
1 more on this story · 1 outlets
- 미생물 분자진단 세니젠, 세계 최초 ‘3대 식중독 원인균 동시 진단키트’ 개발와우테일 · 02:06
-
세니젠, ‘식중독 진단키트’ 특허 출원…세균·바이러스 한 번에 검사
1 more on this story · 1 outlets
- 세니젠, '3대 식중독 원인균' 한 번에 검사…특허 출원알파경제 · Sep 30 16:25
-
단체급식 식중독 사고 잡는 세니젠의 3대 원인균 동시 진단키트 개발
1 more on this story · 1 outlets
- 세니젠, 군 급식용 ‘3대 식중독 원인균 동시 진단키트’ 개발바이오타임즈 · Sep 30 10:31